Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Accounts Payables (2020 - 2025)

Arcutis Biotherapeutics has reported Accounts Payables over the past 6 years, most recently at $12.5 million for Q4 2025.

  • Quarterly results put Accounts Payables at $12.5 million for Q4 2025, down 11.9% from a year ago — trailing twelve months through Dec 2025 was $12.5 million (down 11.9% YoY), and the annual figure for FY2025 was $12.5 million, down 11.9%.
  • Accounts Payables for Q4 2025 was $12.5 million at Arcutis Biotherapeutics, up from $5.8 million in the prior quarter.
  • Over the last five years, Accounts Payables for ARQT hit a ceiling of $24.5 million in Q1 2025 and a floor of $2.7 million in Q2 2021.
  • Median Accounts Payables over the past 5 years was $12.2 million (2022), compared with a mean of $11.2 million.
  • Biggest five-year swings in Accounts Payables: surged 296.25% in 2022 and later plummeted 70.01% in 2025.
  • Arcutis Biotherapeutics' Accounts Payables stood at $7.4 million in 2021, then grew by 20.05% to $8.8 million in 2022, then skyrocketed by 35.86% to $12.0 million in 2023, then increased by 18.58% to $14.2 million in 2024, then decreased by 11.9% to $12.5 million in 2025.
  • The last three reported values for Accounts Payables were $12.5 million (Q4 2025), $5.8 million (Q3 2025), and $15.1 million (Q2 2025) per Business Quant data.